BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021

Pharmaceutical industry veteran brings more than 20 years of business and technical operations experience across various commercial and development products

Chiasma, Inc. announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology Meeting.

Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer (“CSO”).

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology

Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items remaining on the books of the Company.

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 before market open on Thursday, June 3, 2021.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences: William Blair’s 41st Annual Growth Stock Conference Fireside Chat on Tuesday, June 1 st at 11:40 a.m. ET Jefferies Virtual Healthcare Conference Fireside Chat on Friday, June 4 th at 10:00 a.m. ET

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will present at the following investor conferences in June: Jefferies Virtual Healthcare Conference Date: Wednesday, June 2 nd at 2:30 p.m. ET

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as Chief Medical Officer, effective May 24, 2021. With more than 20 years of drug development experience across all phases of drug development,